Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Entecavir of benefit in HBeAg-positive Hep B

    • 17 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      Veenstra DL, Sullivan SD, Clarke L, Iloeje UH, Tafesse E, Di Bisceglie A, Kowdley KV, Gish RG.Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. PharmacoEconomics 25: 963-977, No. 11, 2007

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Entecavir of benefit in HBeAg-positive Hep B. Pharmacoecon. Outcomes News 542, 9 (2007). https://doi.org/10.2165/00151234-200705420-00018

    Download citation

    Keywords

    • Chronic Hepatitis
    • Markov Model
    • Medical Cost
    • Lamivudine
    • Cumulative Incidence